234 related articles for article (PubMed ID: 34293213)
1. Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk.
Tsai CW; Chang WS; Xu Y; Huang M; Bau DT; Gu J
Mol Carcinog; 2021 Nov; 60(11):726-733. PubMed ID: 34293213
[TBL] [Abstract][Full Text] [Related]
2. High circulating insulin-like growth factor-1 reduces the risk of renal cell carcinoma: a Mendelian randomization study.
Chen M; Tsai CW; Chang WS; Xiong GY; Xu Y; Bau DT; Gu J
Carcinogenesis; 2021 Jun; 42(6):826-830. PubMed ID: 33852723
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women.
Murphy N; Knuppel A; Papadimitriou N; Martin RM; Tsilidis KK; Smith-Byrne K; Fensom G; Perez-Cornago A; Travis RC; Key TJ; Gunter MJ
Ann Oncol; 2020 May; 31(5):641-649. PubMed ID: 32169310
[TBL] [Abstract][Full Text] [Related]
4. The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene.
Safarinejad MR; Shafiei N; Safarinejad SH
Arch Toxicol; 2011 Oct; 85(10):1209-18. PubMed ID: 21347663
[TBL] [Abstract][Full Text] [Related]
5. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.
Watts EL; Perez-Cornago A; Fensom GK; Smith-Byrne K; Noor U; Andrews CD; Gunter MJ; Holmes MV; Martin RM; Tsilidis KK; Albanes D; Barricarte A; Bueno-de-Mesquita HB; Cohn BA; Deschasaux-Tanguy M; Dimou NL; Ferrucci L; Flicker L; Freedman ND; Giles GG; Giovannucci EL; Haiman CA; Hankey GJ; Holly JMP; Huang J; Huang WY; Hurwitz LM; Kaaks R; Kubo T; Le Marchand L; MacInnis RJ; Männistö S; Metter EJ; Mikami K; Mucci LA; Olsen AW; Ozasa K; Palli D; Penney KL; Platz EA; Pollak MN; Roobol MJ; Schaefer CA; Schenk JM; Stattin P; Tamakoshi A; Thysell E; Tsai CJ; Touvier M; Van Den Eeden SK; Weiderpass E; Weinstein SJ; Wilkens LR; Yeap BB; ; Allen NE; Key TJ; Travis RC
Int J Epidemiol; 2023 Feb; 52(1):71-86. PubMed ID: 35726641
[TBL] [Abstract][Full Text] [Related]
6. Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.
Bonilla C; Lewis SJ; Rowlands MA; Gaunt TR; Davey Smith G; Gunnell D; Palmer T; Donovan JL; Hamdy FC; Neal DE; Eeles R; Easton D; Kote-Jarai Z; Al Olama AA; Benlloch S; Muir K; Giles GG; Wiklund F; Grönberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Pashayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park J; Kaneva R; Batra J; Teixeira MR; Pandha H; ; Lathrop M; Martin RM; Holly JM
Int J Cancer; 2016 Oct; 139(7):1520-33. PubMed ID: 27225428
[TBL] [Abstract][Full Text] [Related]
7. Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses.
Murphy N; Carreras-Torres R; Song M; Chan AT; Martin RM; Papadimitriou N; Dimou N; Tsilidis KK; Banbury B; Bradbury KE; Besevic J; Rinaldi S; Riboli E; Cross AJ; Travis RC; Agnoli C; Albanes D; Berndt SI; Bézieau S; Bishop DT; Brenner H; Buchanan DD; Onland-Moret NC; Burnett-Hartman A; Campbell PT; Casey G; Castellví-Bel S; Chang-Claude J; Chirlaque MD; de la Chapelle A; English D; Figueiredo JC; Gallinger SJ; Giles GG; Gruber SB; Gsur A; Hampe J; Hampel H; Harrison TA; Hoffmeister M; Hsu L; Huang WY; Huyghe JR; Jenkins MA; Keku TO; Kühn T; Kweon SS; Le Marchand L; Li CI; Li L; Lindblom A; Martín V; Milne RL; Moreno V; Newcomb PA; Offit K; Ogino S; Ose J; Perduca V; Phipps AI; Platz EA; Potter JD; Qu C; Rennert G; Sakoda LC; Schafmayer C; Schoen RE; Slattery ML; Tangen CM; Ulrich CM; van Duijnhoven FJB; Van Guelpen B; Visvanathan K; Vodicka P; Vodickova L; Vymetalkova V; Wang H; White E; Wolk A; Woods MO; Wu AH; Zheng W; Peters U; Gunter MJ
Gastroenterology; 2020 Apr; 158(5):1300-1312.e20. PubMed ID: 31884074
[TBL] [Abstract][Full Text] [Related]
8. Genetically predicted high circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 increase the risks of soft tissue sarcoma.
Xu Y; Tsai CW; Chang WS; Xiong GY; Huang M; Torres KE; Bau DT; Gu J
Am J Cancer Res; 2021; 11(8):3980-3989. PubMed ID: 34522462
[TBL] [Abstract][Full Text] [Related]
9. Circulating concentrations of insulin-like growth factor-I, insulin-like growth factor-binding protein-3, genetic polymorphisms and mammographic density in premenopausal Mexican women: results from the ESMaestras cohort.
Rinaldi S; Biessy C; Hernandez M; Lesueur F; dos-Santos-Silva I; Rice MS; Lajous M; Lopez-Ridaura R; Torres-Mejía G; Romieu I
Int J Cancer; 2014 Mar; 134(6):1436-44. PubMed ID: 24037648
[TBL] [Abstract][Full Text] [Related]
10. Protein QTL analysis of IGF-I and its binding proteins provides insights into growth biology.
Bartell E; Fujimoto M; Khoury JC; Khoury PR; Vedantam S; Astley CM; Hirschhorn JN; Dauber A
Hum Mol Genet; 2020 Aug; 29(15):2625-2636. PubMed ID: 32484228
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans.
Hernandez W; Grenade C; Santos ER; Bonilla C; Ahaghotu C; Kittles RA
Carcinogenesis; 2007 Oct; 28(10):2154-9. PubMed ID: 17724372
[TBL] [Abstract][Full Text] [Related]
12. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.
Gu F; Schumacher FR; Canzian F; Allen NE; Albanes D; Berg CD; Berndt SI; Boeing H; Bueno-de-Mesquita HB; Buring JE; Chabbert-Buffet N; Chanock SJ; Clavel-Chapelon F; Dumeaux V; Gaziano JM; Giovannucci EL; Haiman CA; Hankinson SE; Hayes RB; Henderson BE; Hunter DJ; Hoover RN; Johansson M; Key TJ; Khaw KT; Kolonel LN; Lagiou P; Lee IM; LeMarchand L; Lund E; Ma J; Onland-Moret NC; Overvad K; Rodriguez L; Sacerdote C; Sánchez MJ; Stampfer MJ; Stattin P; Stram DO; Thomas G; Thun MJ; Tjønneland A; Trichopoulos D; Tumino R; Virtamo J; Weinstein SJ; Willett WC; Yeager M; Zhang SM; Kaaks R; Riboli E; Ziegler RG; Kraft P
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2877-87. PubMed ID: 20810604
[TBL] [Abstract][Full Text] [Related]
13. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).
Patel AV; Cheng I; Canzian F; Le Marchand L; Thun MJ; Berg CD; Buring J; Calle EE; Chanock S; Clavel-Chapelon F; Cox DG; Dorronsoro M; Dossus L; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Linseisen J; Lund E; Manjer J; McCarty C; Peeters PH; Pike MC; Pollak M; Riboli E; Stram DO; Tjonneland A; Travis RC; Trichopoulos D; Tumino R; Yeager M; Ziegler RG; Feigelson HS;
PLoS One; 2008 Jul; 3(7):e2578. PubMed ID: 18596909
[TBL] [Abstract][Full Text] [Related]
14. Controversial causal association between IGF family members and osteoporosis: a Mendelian randomization study between UK and FinnGen biobanks.
Tang J; Zhao C; Lin S; Li X; Zhu B; Li Y
Front Endocrinol (Lausanne); 2023; 14():1332803. PubMed ID: 38260127
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients.
Tsai CW; Chang WS; Xu Y; Huang M; Tamboli P; Wood CG; Bau DT; Gu J
Am J Cancer Res; 2022; 12(2):852-860. PubMed ID: 35261807
[TBL] [Abstract][Full Text] [Related]
16. IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women.
D'Aloisio AA; Schroeder JC; North KE; Poole C; West SL; Travlos GS; Baird DD
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):954-66. PubMed ID: 19240240
[TBL] [Abstract][Full Text] [Related]
17. Associations among IGF-1, IGF2, IGF-1R, IGF-2R, IGFBP-3, insulin genetic polymorphisms and central precocious puberty in girls.
Chang HP; Yang SF; Wang SL; Su PH
BMC Endocr Disord; 2018 Sep; 18(1):66. PubMed ID: 30249230
[TBL] [Abstract][Full Text] [Related]
18. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3.
Kaplan RC; Petersen AK; Chen MH; Teumer A; Glazer NL; Döring A; Lam CS; Friedrich N; Newman A; Müller M; Yang Q; Homuth G; Cappola A; Klopp N; Smith H; Ernst F; Psaty BM; Wichmann HE; Sawyer DB; Biffar R; Rotter JI; Gieger C; Sullivan LS; Völzke H; Rice K; Spyroglou A; Kroemer HK; Ida Chen YD; Manolopoulou J; Nauck M; Strickler HD; Goodarzi MO; Reincke M; Pollak MN; Bidlingmaier M; Vasan RS; Wallaschofski H
Hum Mol Genet; 2011 Mar; 20(6):1241-51. PubMed ID: 21216879
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease.
Su X; Colditz GA; Willett WC; Collins LC; Schnitt SJ; Connolly JL; Pollak MN; Rosner B; Tamimi RM
Int J Cancer; 2010 Jan; 126(1):180-90. PubMed ID: 19551864
[TBL] [Abstract][Full Text] [Related]
20. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population.
Cheng I; DeLellis Henderson K; Haiman CA; Kolonel LN; Henderson BE; Freedman ML; Le Marchand L
J Clin Endocrinol Metab; 2007 Sep; 92(9):3660-6. PubMed ID: 17566087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
